Supernus Pharmaceuticals, Inc. (SUPN) — Analysis Summary

Supernus Pharmaceuticals, Inc. (SUPN) has a market cap of $2.76B with year-over-year revenue growth of -0.8%. Net margin stands at 11.2%. The stock trades at a P/E ratio of 37.3.

Key Takeaways

• Revenue changed -0.8% year-over-year
• Net margin of 11.2%
• P/E ratio of 37.3

Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SUPN posted revenue growth of -0.8% and trades at a P/E of 37.3.